Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha
about
Current Advances in Virus-Like Particles as a Vaccination Approach against HIV InfectionImmunomodulatory functions of type I interferonsCan immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?Animal models for HIV/AIDS researchHuman dendritic cells transduced with herpes simplex virus amplicons encoding human immunodeficiency virus type 1 (HIV-1) gp120 elicit adaptive immune responses from human cells engrafted into NOD/SCID mice and confer partial protection against HIV-Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals.Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathwayCD8+ cell depletion accelerates HIV-1 immunopathology in humanized mice.Differential activity of type I interferon subtypes for dendritic cell differentiationA dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication.Concomitant detection of IFNα signature and activated monocyte/dendritic cell precursors in the peripheral blood of IFNα-treated subjects at early times after repeated local cytokine treatments.Type I interferons and their therapeutic role in Th2-regulated inflammatory disorders.Dendritic cells as danger-recognizing biosensors.Molecular adjuvants for mucosal immunity.Transgenic 4-1BBL-engineered vaccine stimulates potent Gag-specific therapeutic and long-term immunity via increased priming of CD44(+)CD62L(high) IL-7R(+) CTLs with up- and downregulation of anti- and pro-apoptosis genes.RNA transfer and its use in dendritic cell-based immunotherapy.Human adaptive immune system Rag2-/-gamma(c)-/- mice.The Ebola Interferon Inhibiting Domains Attenuate and Dysregulate Cell-Mediated Immune Responses.Improving hepatitis B vaccine efficacy in end-stage renal diseases patients and role of adjuvantsEfficient in vitro expansion of human immunodeficiency virus (HIV)-specific T-cell responses by gag mRNA-electroporated dendritic cells from treated and untreated HIV type 1-infected individualsStimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection.IFN-alpha and novel strategies of combination therapy for cancer.Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses.Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs.HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells.Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity.Recent developments in cancer vaccinesIFN-α as a vaccine adjuvant: recent insights into the mechanisms and perspectives for its clinical use.Therapeutic vaccines in renal cell carcinoma.Generation of immunogenic and tolerogenic clinical-grade dendritic cells.Therapeutic vaccines against HIV infection.Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in vivo targeting to dendritic cells.Dendritic cell based vaccines for HIV infection: the way ahead.Type I interferons as regulators of human antigen presenting cell functions.Dendrimers as nonviral vectors in dendritic cell-based immunotherapies against human immunodeficiency virus: steps toward their clinical evaluation.Clinically feasible approaches to potentiating cancer cell-based immunotherapies.Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin.Monocyte derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis.Assessment of migration of HIV-1-loaded dendritic cells labeled with 111In-oxine used as a therapeutic vaccine in HIV-1-infected patients.Fibrocytes are potent stimulators of anti-virus cytotoxic T cells.
P2860
Q26775082-3B4E59A6-47D6-473F-ACBD-C9F2F0D55A04Q26823904-A9C37BBC-ECE8-4A11-8C97-81E9A479CA5DQ26865388-9514097C-780C-49CA-8C8B-C155D8A8E872Q30423656-F72B212F-0949-4BB2-9068-52410BD70B45Q33782430-F835381C-A4DD-4E80-A977-103460C6F558Q33916776-2CCC0CBF-8C4C-4382-A44F-7626BFE2D712Q33920141-D2CF9342-1AA0-4101-AF63-5732D867E9D2Q34433569-5433BD9D-2DF3-4F6D-B5F7-08BBAA1C1145Q34615006-28AD794D-9BC7-46C0-949E-AC94001B8C73Q34646987-0FB759F5-0FB9-4D5E-9006-8CF0994A121EQ35047686-2342CFED-2E1B-411D-803D-EA810C2FB18DQ35753508-018EF06A-AAF5-4E7B-B8F1-A91BB07A43D7Q35790418-1785C251-162E-48DE-9EC2-0F9D254B6DAAQ35826381-D9438FD7-D542-47EC-805B-F425AA312AA4Q35833636-79716216-AB7A-40F8-AC89-AD69AFF5B325Q36065947-815E9C4E-1DE7-4260-AA19-C9AA44B4D148Q36164542-9223BF5A-D9C7-4D40-B2A4-174C6CD18583Q36216308-8132E36C-9CC2-40EE-BE10-37E58365F56EQ36279736-353DC545-3FD0-48F7-8C89-E4F5B2E7361AQ36498151-EC46D660-D1E5-4CDE-912E-69A4BF750EA3Q36568672-0463724B-AEED-4BBC-9309-A02C6EB04FA7Q36849152-E7D826CA-983D-42A9-A5EA-FB489D13F1C4Q37033299-D6471DAD-FCA8-4130-A626-B57F159E19D0Q37173478-A618D4E2-434E-45D2-9D68-2668981E0290Q37422657-F68B0E3D-9786-484E-844A-BDB762FE117EQ37699345-ACB5BBE3-5C17-4AA6-9869-7496BC0F5D6FQ37830226-85937E95-E481-4324-8228-D8B79186BB78Q37867104-D0D41A63-71B9-4FE0-B91C-309244517D98Q37922585-27D1D2D8-C943-4205-92BA-2CEE1A2A82D0Q37959362-1BB546BA-EFA6-49A7-A0C3-96E2A14894A5Q38013505-33F99FD8-95D1-494F-ADF6-6261D2710AFFQ38059499-3E9D4B97-79D1-4D0B-A2E6-3387785138BAQ38126373-915E516B-C5C4-4DD0-9811-B287AD31E3F8Q38215320-5461753B-E35C-450E-924E-D0BE1A54C351Q38296086-C69DB653-3AB5-4D56-A9F9-AEB71BD1A10BQ38453610-FC4DBB04-FFE6-4B41-9173-D37FF1484288Q39303806-7506C427-F3CD-408D-8A1D-ADD9815CA713Q39755645-C52B70C1-EDCF-447B-AE2B-2ABEDFEF4817Q39984018-0E864A55-811A-45EE-9B2F-CB7C5EE597BBQ40513059-31A70C27-66F0-467F-9AFB-FFC15C623109
P2860
Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Potent immune response against ...... d in the presence of IFN-alpha
@ast
Potent immune response against ...... d in the presence of IFN-alpha
@en
type
label
Potent immune response against ...... d in the presence of IFN-alpha
@ast
Potent immune response against ...... d in the presence of IFN-alpha
@en
prefLabel
Potent immune response against ...... d in the presence of IFN-alpha
@ast
Potent immune response against ...... d in the presence of IFN-alpha
@en
P2093
P2860
P50
P356
P1476
Potent immune response against ...... d in the presence of IFN-alpha
@en
P2093
Mariantonia Logozzi
Massimo Spada
Tiziana Di Pucchio
P2860
P304
P356
10.1084/JEM.20021924
P407
P577
2003-07-01T00:00:00Z